Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:49 PM
Ignite Modification Date: 2025-12-24 @ 11:49 PM
NCT ID: NCT03016351
Eligibility Criteria: Inclusion Criteria: * Sedentary * Body Mass Index of 18.5-40 kg/m² * Born in the United States of either two African-American or two non-Hispanic Caucasian parents * Blood pressure of at least 120/80 mmHg Exclusion Criteria: * Inability to give informed consent * History of cardiovascular disease or cardiovascular events * Hypertension (systolic \>159 mmHg and diastolic \>99 mmHg) or on more than one anti-hypertensive medication * Diabetes Type I\& II * Hyperlipidemia, with an LDL-C \>159 mg/dL and /or total-C \>229 mg/dL * Pregnancy (or intend to become pregnant while participating in study) or nursing * Tobacco use in the past 6 months (including, but not limited to cigarettes, e-cigarettes, hookah, Nicorette, SNUs and chewing tobacco) * Chronic inflammatory disease such as, but not limited to, cancer * Chronic autoimmune diseases such as, but not limited to: lupus, multiple sclerosis, rheumatoid arthritis * Adverse reaction to nitroglycerin * Anemia with a hemoglobin \< 8 * Head injury within last 6 months * Seizure disorder * Presence of renal disease with a creatinine \> 1.5mg/dL * Presence of liver disease with liver enzymes \> 3x the upper limits of normal * Currently abusing alcohol or illicit drugs * Unreliability as a study subject, in the opinion of the Investigator * Lidocaine allergy * Amenorrhea * Postmenopausal women
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 55 Years
Study: NCT03016351
Study Brief:
Protocol Section: NCT03016351